Clinical Trials Browser

Terminated × OTHER × Docetaxel × Clear all

NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Phase 2 Terminated

15 enrolled 11 charts

Prostatic Neoplasms

NCT05567835 2026-04-09

TOGAR

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

Head and Neck Neoplasms

NCT04037527 2026-02-04

Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

Phase 1 Terminated

Sarcoma

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT02688803 2025-12-04

OTT15-04

Phase 4 Terminated

2 enrolled 4 charts

Breast Neoplasms

NCT04396535 2025-11-17

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

10 enrolled 17 charts

Lung Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Phase 2 Terminated

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT01382706 2025-10-09

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Phase 2 Terminated

15 enrolled 10 charts

Urinary Bladder Neoplasms

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Phase 2 Terminated

ATM Gene Mutation

NCT00253318 2025-04-27

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT03764540 2025-04-13

CABPOSTAAT

Phase 2 Terminated

Prostatic Neoplasms

NCT02485834 2025-01-20

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Phase 2 Terminated

5 enrolled 11 charts

Gastrointestinal

Stomach Neoplasms

NCT04937738 2024-11-06

PECORINO

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT05156905 2024-10-09

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

Prostatic Neoplasms

NCT04583488 2024-08-09

Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis

Phase 1 Terminated

GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT03393741 2024-06-25

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Breast Neoplasms

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03066154 2024-06-03

DOP

Phase 1 Terminated

Prostatic Neoplasms

NCT00617656 2024-01-30

BREC

Phase 3 Terminated

382 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00176631 2023-12-22

Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

10 enrolled 6 charts

Prostatic Neoplasms

NCT03837353 2023-12-18

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Phase 1/2 Terminated

18 enrolled 15 charts

Prostatic Neoplasms

NCT03228186 2023-10-23

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

Phase 2 Terminated

40 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Phase 2 Terminated

3 enrolled 6 charts

Breast Neoplasms

NCT03737123 2023-09-13

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

6 enrolled 18 charts

Carcinoma, Transitional Cell

NCT02524275 2023-09-08

Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Terminated

14 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck

NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Phase 2 Terminated

7 enrolled 10 charts

Locally Advanced Breast Cancer

NCT00118131 2023-08-15

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2 Terminated

49 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00786682 2023-08-14

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

Phase 2 Terminated

11 enrolled 7 charts

Prostatic Neoplasms

NCT02516670 2023-06-07

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Phase 2 Terminated

50 enrolled 15 charts

Prostatic Neoplasms

NCT02124902 2022-11-07

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

Phase 2 Terminated

148 enrolled 9 charts

Triple Negative Breast Neoplasms

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT03041181 2022-07-11

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Phase 2 Terminated

3 enrolled 11 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT01929811 2022-04-06

NeoMET

Phase 2 Terminated

pCR Rate

NCT02565901 2021-10-01

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

28 enrolled 8 charts

Prostatic Neoplasms

NCT03894007 2021-09-23

PREDIXIIHER2

Phase 2 Terminated

Breast Neoplasms

NCT02985021 2021-08-05

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Phase 2 Terminated

2 enrolled 5 charts

Prostatic Neoplasms

NCT02685267 2021-04-09

Doce/Enza

Phase 2 Terminated

9 enrolled 11 charts

Prostatic Neoplasms

NCT00066677 2021-03-05

Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Phase 2 Terminated

32 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT03256721 2021-02-08

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00285415 2021-02-05

A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

Phase 2 Terminated

Advanced Endometrial Adenocarcinoma, Stage III A, B, C

NCT02145078 2020-09-24

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Phase NA Terminated

4 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT03827473 2020-06-25

ACADEMIC

Phase 2 Terminated

1 enrolled 6 charts

Prostatic Neoplasms

NCT03093272 2020-04-09

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

Phase 2 Terminated

9 enrolled 15 charts

Prostatic Neoplasms

NCT03043989 2020-02-17

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Phase 1 Terminated

Prostatic Neoplasms

NCT00582582 2019-12-13

Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer

Phase 2 Terminated

Neoplasm Metastasis, Prostatic Neoplasms

NCT02110992 2019-11-25

Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

Phase 1 Terminated

Head and Neck Neoplasms

NCT02076594 2019-10-09

Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

Phase 3 Terminated

Gastrointestinal

Stomach Neoplasms